A Phase I study to evaluate the pharmacokinetics, safety, and tolerability of multiple oral doses of obefazimod in patients with mild and moderate hepatic impairment, compared to matched control groups.
This research is an early-stage study, called a Phase I trial, looking into a new medication named obefazimod. Doctors are hoping this medicine could help people with conditions like ulcerative colitis (a type of inflammatory bowel disease) and rheumatoid arthritis (a type of arthritis). The main goal of this particular study is to understand how the body handles obefazimod, especially in people who have mild or moderate liver problems, compared to people with normal liver function. This helps researchers figure out the safest way to use the medicine and what doses might be right. It's a key step to ensure the medicine is safe and well-tolerated before it can be studied in more people.
At a glance
What is this study about?
This study is an early step in testing a new medicine called obefazimod. Think of it like taking a new car for its first test drive – we're learning how it handles on the road. Researchers believe obefazimod might help people who have inflammatory conditions, such as ulcerative colitis, which affects the bowel, and rheumatoid arthritis, which affects the joints.
The main purpose of this study is to see how the body processes obefazimod. Specifically, it focuses on how people with some liver difficulty handle the medicine compared to people whose livers are working normally. This is really important because the liver plays a big role in breaking down medicines. Understanding this helps doctors figure out if people with liver problems might need a different dose of obefazimod or if it's safe for them to take at all. This careful checking is a crucial step to make sure any new medicine is as safe and effective as possible for everyone.
This kind of study, called a Phase I trial, is usually done with a small group of people. It's not designed to see if the medicine treats the disease yet, but rather to gather basic safety information and learn how much of the medicine gets into the blood, how long it stays there, and how the body gets rid of it. This essential information will guide future, larger studies to see if obefazimod can actually treat these conditions.
Key takeaways
- This is an early-stage study (Phase I) for a new medicine called obefazimod.
- It aims to understand how the body handles obefazimod, especially in people with liver problems.
- The medicine is being explored for conditions like ulcerative colitis and rheumatoid arthritis.
- The study mainly checks for safety and how the medicine moves through the body.
- You must be 18 years or older to participate.
- Participating is voluntary, and you can withdraw at any time.
Who may be eligible?
To join this study, you need to be an adult, aged 18 years or older. Both men and women are welcome to take part.
Since this study is specifically looking at how the medicine works in people with liver problems, you might be asked to provide information about your liver health. The study team will check if your liver condition is mild or moderate, or if your liver is working normally.
There might be other health requirements too, which the study team will discuss with you. These are put in place to ensure your safety and that the study results are clear and helpful.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Are you willing to take an oral study medicine?
- Are you able to attend several clinic visits for checks and blood tests?
- Do you have mild or moderate liver problems, or healthy liver function?
- Are you open to discussing your full medical history with the study team?
What does participation involve?
If you decide to take part, you would receive the study medicine, obefazimod, by mouth. This study is focused on how your body handles the medicine, so you would have several visits to the clinic. During these visits, doctors and nurses would perform regular health checks, such as measuring your blood pressure and taking blood samples. These blood samples help them understand how the medicine is moving through your body and how your liver is processing it. You would also be asked about any side effects you might experience. The total length of your involvement in the study would be explained to you by the research team.
Potential risks and benefits
Locations (1)
- —UnverifiedGermany
Common questions
What does 'Phase I study' mean?
A Phase I study is one of the earliest steps in testing a new medicine in people. It's mainly about checking if the medicine is safe and how the body handles it, rather than seeing if it treats a disease yet.
What is obefazimod?
Obefazimod is the name of the new medicine being tested in this study. Researchers hope it could help with inflammatory conditions like ulcerative colitis and rheumatoid arthritis.
Why are you studying people with liver problems?
The liver helps process medicines in the body. By studying people with and without liver problems, the researchers can understand how liver health might affect how obefazimod works, which is vital for safe dosing.
Will this medicine cure my condition?
This early-stage study is not designed to find out if obefazimod cures conditions. Its main purpose is to gather information about safety and how the body handles the medicine.
Do I have to take part?
No, taking part in any medical study is completely your choice. You can decide not to join, or you can leave the study at any time, without it affecting your usual medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.